AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2321-2330

  Zhou, Yuanfeng ^a   Chen, Yi ^a   Tong, Linjiang ^a   Xie, Hua ^a   Wen, Weiwei ^a   Zhang, Jie ^a   Xi, Yong ^a   Shen, Yanyan ^a   Geng, Meiyu ^a   Wang, Yuanyuan ^a   Jiang, Hualiang ^a   Luo, Cheng ^a   Lin, Liping ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Angiogenesis; Anti tumour activity; Multi tyrosine kinases inhibitor

Indexed keywords

6 ((7 ((1 AMINOCYCLOPROPYL)METHOXY) 6 METHOXY 4 QUINOLYL)OXY) N METHYL NAPHTHALENE 1 CARBOXAMIDE; 6-((7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXY-4-QUINOLYL)OXY)-N-METHYL-NAPHTHALENE-1-CARBOXAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 1; NAPHTHALENE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NAPHTHALENES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

RATTUS;

EID: 84863112637     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01541.x     Document Type: Article

References (36)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-10.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007; 6: 273-86.
3. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006; 12: 5018-22.
4. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246: 1309-12.
5. Lamoreaux WJ, Fitzqerald ME, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998; 55: 29-42.
6. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996; 49: 138-62.
7. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptor in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006; 312: 549-60.
8. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22: 1276-312.
9. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003; 9: 685-93.
10. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998; 125: 1591-8.
11. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumour vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004; 18: 338-40.
12. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 159-78.
13. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998; 141: 1659-73.
14. Tsunoda S, Nakamuia T, Sakurai H, et al. Fibrolast growth factor-2-induced host stroma reaction during initial tumour growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci. 2007; 98: 541-8.
15. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010; 13: 1-14.
16. Cao H, Zhang H, Zheng X, et al. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family. J Mol Graph Model. 2007; 26: 236-45.
17. Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumour activity in multiple preclinical models. Cancer Res. 2011; 71: 1396-405.
18. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res. 2004; 64: 7099-109.
19. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Inves. 1973; 52: 2745-56.
20. Zhang YX, Chen Y, Guo XN, et al. 11, 11′-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumour activity. Anticancer Drugs. 2005; 16: 515-24.
21. Guo XN, Zhong L, Zhang XH, et al. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim Biophys Acta. 2004; 1673: 186-93.
22. Bernstein FC, Koetzle TF, Williams GJ, et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol. 1977; 112: 535-42.
23. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47: 1739-49.
24. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995; 8: 127-34.
25. DeLano WL. The pymol user's manual. San Carlos, CA: DeLano Scientific; 2002.
26. Poirel L, Laqrutta E, Taylor P, et al. Emergence of metallo-ss-lactamase NDM-1-producing multidrug resistant Escherichia coli in Australia. Antimicrob Agents Chemother. 2010; 54: 4914-6.
27. Yang X, Luo P, Yang B, et al. Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin. Pharmacol Res. 2006; 54: 334-40.
28. Staton CA, Stribbling SM, Tazzyman S, et al. Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol. 2004; 85: 233-48.
29. Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 2009; 12: 114-26.
30. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumours. Cancer Cell. 2005; 8: 299-309.
31. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumour vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95.
32. Raza A, Franklin MJ, Dudek AZ, et al. Pericytes and vessel maturation during tumour angiogenesis and metastasis. Am J Hematol. 2010; 85: 593-8.
33. Klosowska-Wardega A, Hasumi Y, Burmakin A, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One. 2009; 4: e8149.
34. Kuhnert F, Tam BY, Sennino Bet al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumour angiogenesis. Proc Natl Acad Sci. 2008; 105: 10185-90.
35. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006; 7: 358-64.
36. Fiebig HH, Schuchhardt C, Henss H, et al. Comparison of tumour response in nude mice and in the patients. Behring Inst Mitt. 1984; 74: 343-52.